THE LONG-TERM RISKS AND BENEFITS OF HORMONE REPLACEMENT THERAPY
Open Access
- 1 August 1991
- journal article
- review article
- Published by Hindawi Limited in Journal of Clinical Pharmacy & Therapeutics
- Vol. 16 (4) , 231-245
- https://doi.org/10.1111/j.1365-2710.1991.tb00310.x
Abstract
There is increasing awareness that the long-term consequences of ovarian failure can be prevented or reduced with appropriate hormone replacement therapy (HRT). After the menopause, there is a rapid loss of trabecular bone resulting in a one in two lifetime risk of osteoporotic fracture. HRT prevents this bone loss and decreases the incidence of fracture. A minimum of 5 years treatment is recommended for significant benefit. Epidemiological evidence is accumulating that post-menopausal oestrogen therapy reduces the risk of cardiovascular disease and stroke by between 30 and 70% even in the presence of established risk factors. Given the prevalence of cardiovascular disease, this is likely to be one of the principle benefits of HRT in the next decade. Concerns about the long-term safety of HRT have focused on endometrial and breast cancer. The increase in risk of endometrial cancer associated with oestrogen only therapy is abolished with the sequential addition of a progestogen for 10-12 days each cycle. The possible effect of HRT on breast cancer risk has to be considered against the background of a one in 12 lifetime risk of developing this disease. The epidemiological studies investigating this relationship are reviewed in this paper. There is a broad consensus that 5-6 years duration of HRT does not increase breast cancer risk. Longer durations of therapy (10-15 years) have been reported to increase this risk although not all the data are in agreement. Other factors, such as family history and benign breast disease, may also influence the risk of breast cancer. The potential benefits of HRT on mortality and morbidity are enormous. Against this is a possible small increase in breast cancer risk with long-term usage. Greater awareness of the long term consequences of the menopause and the potential benefits of HRT should be encouraged so that women can make informed decisions about their need for HRT.Keywords
This publication has 42 references indexed in Scilit:
- The Risk of Breast Cancer after Estrogen and Estrogen–Progestin ReplacementNew England Journal of Medicine, 1989
- The role of oestrogens and progestagens in the epidemiology and prevention of breast cancerEuropean Journal of Cancer and Clinical Oncology, 1988
- Hip Fracture and the Use of Estrogens in Postmenopausal WomenNew England Journal of Medicine, 1987
- Involutional OsteoporosisNew England Journal of Medicine, 1986
- A Prospective Study of Postmenopausal Estrogen Therapy and Coronary Heart DiseaseNew England Journal of Medicine, 1985
- Effect of Estrogen/Progestin Potency on Lipid/Lipoprotein CholesterolNew England Journal of Medicine, 1983
- Effects of Different Progestogens on Lipoproteins during Postmenopausal Replacement TherapyNew England Journal of Medicine, 1981
- Expansion of Fc receptor-bearing T lymphocytes in patients with immunoglobulin G and immunoglobulin A myeloma.Journal of Clinical Investigation, 1981
- Decreased Risk of Fractures of the Hip and Lower Forearm with Postmenopausal Use of EstrogenNew England Journal of Medicine, 1980
- Estrogen Use in Postmenopausal Women — Costs, Risks, and BenefitsNew England Journal of Medicine, 1980